For the Inventor, By the Inventor

Enter assignee name

Austin, TX, United States of America

Molecular Templates, Inc.

USPTO Granted Patents = 27

% Expired Patents = 11.1

EPO Patents = 17

Forward Citations = 80

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Erin Willert (21 out of 23 patents)

Eric Poma (21 out of 21 patents)

Jason Kim (8 out of 8 patents)

4. Jack Higgins (8 out of 8 patents)

5. Sangeetha Rajagopalan (6 out of 6 patents)

6. Garrett Lee Robinson (4 out of 4 patents)

7. Brigitte Brieschke (4 out of 4 patents)

8. Jensing Liu (4 out of 4 patents)

9. Rodney Flores-Lefranc (3 out of 3 patents)

10. Hilario Ramos (3 out of 3 patents)

11. Jian-Xin Duan (3 out of 18 patents)

12. Mark D Matteucci (3 out of 65 patents)

13. Richard Shimkets (2 out of 3 patents)

14. Crystal Jackson (2 out of 3 patents)

15. Thomas Vincent (2 out of 3 patents)

Core Competencies:

Biopharmaceuticals

Shiga Toxin

Effector Polypeptides

CD20-Binding Molecules

Hypoxia-Activated Therapy

Cell-Targeting Molecules

PD-L1-Binding Molecules

MHC Class I

Cytotoxic Libraries

Multivalent Molecules

Protease-Cleavage Resistant

Predictive Biomarkers

27 patents: Sort by Forward Citations

1. 12637495 - DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS (2026-05-26),

2. 12180284 - Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector (2024-12-31),

3. 12180262 - CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors (2024-12-31),

4. 12065469 - De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals (2024-08-20),

5. 12037367 - MHC class I epitope delivering polypeptides (2024-07-16),

6. 11918649 - PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds (2024-03-05),

7. 11857628 - Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation (2024-01-02),

8. 11713347 - CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors (2023-08-01),

9. 11406692 - Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes (2022-08-09),

10. 11389542 - Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation (2022-07-19),

11. 11365223 - De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same (2022-06-21),

12. 11312751 - MHC class I epitope delivering polypeptides (2022-04-26),

13. 11248061 - Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereof (2022-02-15),

14. 11225509 - HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds (2022-01-18),

15. 11142584 - CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same (2021-10-12),

Molecular Templates, Inc. is a biotechnology company based in Austin, Texas, specializing in the development of innovative therapeutics for cancer treatment. The company focuses on its proprietary technology platform, which utilizes engineered proteins to create targeted therapies that aim to enhance the efficacy and safety of cancer treatments. By leveraging advanced molecular design and engineering, Molecular Templates is dedicated to advancing the field of oncology and improving patient outcomes through precision medicine.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Molecular Templates, Inc.

27 Patents

#113 in Austin, TX

#710 in Texas

#12,405 in US

#23,968 in the World

Austin, TX, United States of America

Molecular Templates, Inc.

Forward Citations = 80

29 inventors:

Erin Willert (21 out of 23 patents)

Eric Poma (21 out of 21 patents)

Jason Kim (8 out of 8 patents)

4. Jack Higgins (8 out of 8 patents)

5. Sangeetha Rajagopalan (6 out of 6 patents)

Please report any incorrect information to [email protected]

Loading…